Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESSO 43 | ESSO43 highlights: advancements in breast cancer treatment and emphasis on individualized care

Mariela Vasileva-Slaveva • 4 Oct 2024
ESSO 43
Breast Cancer

Mariela Vasileva-Slaveva, MD, PhD, University Hospital Alexandrovska, Sofia, Bulgaria, discusses the key highlights of the conference, touching on advancements in breast cancer treatment, including the role of patient-reported outcomes, non-surgical options after neoadjuvant therapy, and the importance of individualized patient care. This interview took place at the ESSO 43 congress in Antwerp, Belgium.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mariela Vasileva-Slaveva

ESSO43: collaboration, inclusiveness, and advances in multidisciplinary cancer care
2:12
ESSO43: collaboration, inclusiveness, and advances in multidisciplinary cancer care
Mariela Vasileva-Slaveva • 4 Oct 2024
Breast conservation benefits: oncoplastic surgery, autologous challenges, and implant complications
0:43
Breast conservation benefits: oncoplastic surgery, autologous challenges, and implant complications
Mariela Vasileva-Slaveva • 4 Oct 2024
Men with breast cancer: biology and diagnosis in Eastern Europe
3:20
Men with breast cancer: biology and diagnosis in Eastern Europe
Mariela Vasileva-Slaveva • 14 May 2021

Related Videos

CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals